Drugs Information:
Neratinib
Basic Information
|
|
||
| ID | DDInter1281 | |
| Drug Type | small molecule | |
| Molecular Formula | C30H29ClN6O3 | |
| Molecular Weight | 557.050 | |
| CAS Number | 698387-09-6 | |
| Description | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | |
| ATC Classification | L01EH02 | |
| IUPAC Name | (2E)-N-[4-({3-chloro-4-[(pyridin-2-yl)methoxy]phenyl}amino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide | |
| InChI | JWNPDZNEKVCWMY-VQHVLOKHSA-N | |
| Canonical SMILES | CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N | |
| Useful Links | DrugBank ChEBI PubChem Substance ChemSpider BindingDB Wikipedia ChEMBL ZINC | |
Interactions with
Neratinib
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|